Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228626 | 0.92 | GRIN2B (0.48) | GRIN2BMMP2MMP9KDM4EALDH1A1 | |
| SCHEMBL2229355 | 0.89 | GRIN2B (0.42) | GRIN2BNOS1NOS2MMP2MMP9 | |
| Trifluoroacetic Acid SCHEMBL2287813 | 0.87 | GRIN2B (0.47) | GRIN2BMMP2MMP9KDM4EALDH1A1 | |
| SCHEMBL2229199 | 0.87 | MMP2 (0.46) | GRIN2BNOS1NOS2MMP2MMP9 | |
| SCHEMBL2228034 | 0.86 | GRIN2B (0.41) | GRIN2BMMP2MMP9KCNA5ENPP2 | |
| SCHEMBL2229512 | 0.85 | MAPT (0.50) | GRIN2BMMP2MMP9KDM4EALDH1A1 | |
| SCHEMBL2227267 | 0.85 | GRIN2B (0.44) | GRIN2BMMP2MMP9KDM4EALDH1A1 | |
| SCHEMBL2230339 | 0.85 | GRIN2B (0.45) | GRIN2BNOS1NOS2MMP2MMP9 | |
| SCHEMBL2227918 | 0.84 | GRIN2B (0.44) | GRIN2BMMP2MMP9KDM4EALDH1A1 | |
| SCHEMBL2230319 | 0.83 | GRIN2B (0.44) | GRIN2BNOS1NOS2NOS3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000010-B2 | Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2015-04-07 | — | — | US | claimed |
| EP-2526100-B1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2013-12-04 | — | — | EP | claimed |
| US-20120295909-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2012-11-22 | — | — | US | claimed |
| WO-2011089550-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI AVENTIS (FR) | 2011-07-28 | — | — | WO | claimed |
| US-9000010-B2 | Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2015-04-07 | — | — | US | disclosed |
| EP-2526100-B1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2013-12-04 | — | — | EP | disclosed |
| US-20120295909-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2012-11-22 | — | — | US | disclosed |
| WO-2011089550-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI AVENTIS (FR) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295909-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | PRMT9, PRMT8, CBR1 | GRIN2B 362/4885NOS1 525/4885NOS2 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.